

Supplementary Materials:

Table S1. Cytogenetic Scoring System in MDS patients

Cytogenetic Scoring System in MDS ¹ Patients				
Prognostic cytogenetic subgroups	Percentage of patients, %	Karyotype	Median survival, years	Median time to 25% AML ² evolution, years
Very Good	4	–Y, del(11q)	5.4	NR ³
Good	72	Normal, del(5q), del(12p), del(20q), double including del(5q)	4.8	9.4
Intermediate	13	del(7q), +8, +19, i(17q), any other single or double independent clones	2.7	2.5
Poor	4	–7, inv(3)/t(3q)/del(3q), double including –7/del(7q), complex: 3 abnormalities	1.5	1.7
Very Poor	7	Complex: > 3 abnormalities	0.7	0.7

¹MDS myelodysplastic syndrome; ²AML acute myeloid leukemia; ³NR not reached

Table S2. IPSS-R prognostic values

IPSS-R ¹ prognostic score values							
Prognostic value	0 points	0.5 points	1 points	1.5 points	2 points	3 points	4 points
Cytogenetics*	Very Good	–	Good	–	Intermediate	Poor	Very Poor
BM ² blasts, %	≤ 2	–	> 2 to < 5	–	5 to 10	> 10	–
Hemoglobin, g/dL	≥ 10	–	8 to < 10	< 8	–	–	–
Platelets, ×10 ⁹ /L	≥ 100	50 to < 100	< 50	–	–	–	–
ANC ³ , ×10 ⁹ /L	≥ 0.8	< 0.8	–	–	–	–	–

*According to Table 4

– indicates not applicable

¹IPSS-R revised International Prognostic Scoring System; ²BM bone marrow; ³ANC absolute neutrophil count

TableS 3. IPSS-R prognostic risk categories and scores

IPSS-R ¹ prognostic risk categories/scores	
Risk category	Risk score
Very Low	≤ 1.5
Low	> 1.5-3
Intermediate	> 3-4.5
High	> 4.5-6
Very High	> 6

¹IPSS-R revised International Prognostic System